Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CT1812 in mild to moderate Alzheimer's disease
NCT02907567Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc.. Started Sep 2016; status: completed.
02
Drugs
pirfenidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02907567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907567.